Butterfly Network, Inc. filings document the formal disclosures of a public digital health company built around Ultrasound-on-Chip devices, ultrasound software and AI. Recent 8-K reports furnish quarterly and annual results, business updates, material agreements, executive and director matters, and listing-status notices affecting securities issued in connection with its prior business combination with Longview Acquisition Corp.
Proxy materials describe annual meeting proposals, director elections, auditor ratification and executive-compensation votes. Other filings cover the company’s Class A common stock, public warrants, capital structure and governance, including the NYSE Form 25 record for removal of the warrants from listing and registration, while operating disclosures address point-of-care ultrasound and Butterfly Embedded licensing activity.
Butterfly Network, Inc. President & CEO Joseph DeVivo reported two equity transactions in Class A Common Stock. On March 2, 2026, he acquired 1,424,534 restricted stock units (RSUs) at $0 per share as a grant, each RSU representing one share upon vesting. According to the disclosure, these RSUs vest in three equal annual installments beginning March 1, 2027, subject to his continued service.
On March 3, 2026, he sold 161,275 shares of Class A Common Stock in an open-market transaction at a weighted average price of $3.712 per share, with individual sale prices ranging from $3.575 to $3.80 per share. The company states it has a sell-to-cover policy and that these sales were automatically executed solely to satisfy tax withholding obligations related to RSU vesting and were not at his discretion. After the reported sale, his directly held stake was 8,513,048 shares of Class A Common Stock.
Butterfly Network, Inc. deputy general counsel Nicholas Caezza reported equity compensation and a related tax sale. He was granted 89,359 restricted stock units, each representing one share of Class A common stock, vesting in three equal annual installments beginning on March 1, 2027, subject to continued service.
To cover tax withholding from RSU vesting under the company’s sell-to-cover policy, he automatically sold 14,209 Class A shares in an open-market transaction at a weighted average price of $3.712 per share, with prices ranging from $3.575 to $3.80. Following these transactions, he directly held 312,040 shares, including 5,855 shares acquired under the employee stock purchase plan on December 31, 2025.
Butterfly Network, Inc. CAO and SVP, Finance Megan Carlson reported one stock grant and one stock sale involving Class A Common Stock. On March 2, 2026, she acquired 97,883 restricted stock units, each representing one share, which vest in three equal annual installments beginning on March 1, 2027, subject to her continued service. On March 3, 2026, she sold 41,978 shares in an open-market transaction at a weighted average price of $3.712 per share, with sale prices ranging from $3.575 to $3.80. The company states these sales were automatic under a “sell-to-cover” policy to satisfy tax withholding on RSU vesting, and not at her discretion. After these transactions, she directly held 617,631 shares, which includes 14,282 shares previously acquired under the employee stock purchase plan.
BFLY filing reports an affiliate sale notification for Class A shares. The notice lists 42,540 Class A shares connected to a restricted stock vesting on 03/02/2026 and records a proposed sale under that vesting event.
The filing also discloses that Steven Cashman sold 250,000 Class A shares on 02/26/2026 for 1087050.30. The filing is a routine Form 144 notice of proposed sale by an affiliate.
Butterfly Network Chief Business Officer Steve Cashman reported an open-market sale of 250,000 shares of Class A common stock. The sale occurred at a weighted average price of $4.348 per share, with individual prices between $3.99 and $4.955, under a Rule 10b5-1 trading plan. After this transaction, he holds 1,931,884 shares directly.
Butterfly Network, Inc. reports 2025 annual results, highlighting growth in its handheld ultrasound and software platform. Revenue rose to $97.6 million from $82.1 million in 2024, driven by its Ultrasound‑on‑Chip™ devices, enterprise software, and emerging home-care and veterinary offerings.
The company remains unprofitable, posting a net loss of $77.1 million, and continues to invest in AI tools, global expansion and its Butterfly Embedded™ co‑development program. Butterfly had about 220 employees as of January 31, 2026 and sells in over 30 countries, positioning its technology as a lower-cost alternative to traditional cart-based ultrasound.